TransThera Sciences (Nanjing), Inc. (HKG:2617)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
56.30
-1.15 (-2.00%)
Apr 28, 2026, 4:08 PM HKT
Market Cap 22.75B
Revenue (ttm) n/a
Net Income (ttm) -329.35M
Shares Out 404.08M
EPS (ttm) -0.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,015,300
Average Volume 1,312,800
Open 58.95
Previous Close 57.45
Day's Range 56.10 - 61.85
52-Week Range 20.20 - 679.50
Beta n/a
RSI 28.94
Earnings Date Mar 31, 2026

About HKG:2617

TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating ... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 121
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2617
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.